<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79172">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074774</url>
  </required_header>
  <id_info>
    <org_study_id>RP-NIAE2014001Reg</org_study_id>
    <nct_id>NCT02074774</nct_id>
  </id_info>
  <brief_title>IntellO2 vs Manual Control for Optimizing Oxygenation in Infants</brief_title>
  <official_title>Comparison of the IntellO2 - Precision Flow Automatic FiO2 Controller to Manual Control for Optimizing Oxygenation in Preterm Infants Receiving High Flow Nasal Cannula Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vapotherm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ashford and St. Peter's Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vapotherm, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to demonstrate that the IntellO2 device providing
      automated control of fraction of inspired oxygen (FiO2) adjustments in spontaneously
      breathing infants with fluctuating arterial blood oxygen saturation levels is safe and
      efficacious in the routine clinical environment. Specifically, it is hypothesized that the
      IntellO2 will perform as well or better than standard practice for maintaining infants'
      arterial blood oxygen saturation in a target range while minimizing the exposure to elevated
      levels of oxygen in the inspired gas.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent time in target range for oxygen saturation by pulse oximetry</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Oxygen Titration in Preterm Infants to Manage Lung Disease</condition>
  <arm_group>
    <arm_group_label>Aeolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated control of FiO2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manual control of FiO2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aeolus</intervention_name>
    <description>Automated FiO2 regulator that responds to pulse oximetry measures</description>
    <arm_group_label>Aeolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual control</intervention_name>
    <description>Standard practice of manually titrating FiO2 as needed.</description>
    <arm_group_label>Manual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Preterm infants being treated with high flow nasal cannula therapy

          2. A need for supplemental oxygen as demonstrated by an required FiO2 &gt; 0.25 at
             enrollment

          3. Requiring a flow rate of greater than 2 L/min such that the assumed inspired oxygen
             fraction matched delivered oxygen fraction (definition of HFNC).

        Exclusion Criteria:

          1. Major congenital abnormalities

          2. Hemodynamic instability, defined as being outside of a normotensive range based on
             each infant's individual characteristics

          3. Seizures

          4. Ongoing sepsis

          5. Meningitis

          6. Clinician's concern regarding stability of the infant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Reynolds, MBBS FRCPCH PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ashford and St. Peter's Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Miller, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Vapotherm, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Reynolds, MBBS FRCPCH PhD</last_name>
    <phone>01932723495</phone>
    <email>peter.reynolds@asph.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Miller, Ph.D</last_name>
    <phone>1 (856) 279-1227</phone>
    <email>tom.miller@vtherm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>N. Kevin Ives, MD FRCPCH</last_name>
      <phone>+44770474615</phone>
      <email>kevin.ives@nhs.net</email>
    </contact>
    <investigator>
      <last_name>N. Kevin Ives, MD FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashford and St. Peter's Hospitals NHS Trust</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Reynolds, MB.BS FRCPCH PhD</last_name>
      <phone>01932723495</phone>
      <email>peter.reynolds@asph.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Peter Reynolds, MB.BS FRCPCH PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 13, 2016</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal cannula, high flow oxygen therapy, pulse oximetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
